Destiny Pharma's nasal spray project already delivering "more than hoped for" - Neil Clark , CEO, Destiny Pharma 00:00:00

Share On Facebook Share On Twitter

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza.

Recent Videos